Kushe told CNBC-TV18, "I like Indraprastha Medical because it's comparatively undervalued to its peers. The leaders in the sector are Fortis and Apollo Health; Apollo is valued almost twice its sales or revenues and Fortis is valued almost three times its sales or revenues while Indraprastha is valued 0.75 to its sales - that is number one. The second reason that I like about Indraprastha is that it has got time and price target and that will rise above Rs 43 by around 18th November or 2nd December. I think it should do it comfortably by 18th November then the upside targets are around Rs 50; first target is Rs 50 then Rs 60 and then maybe a final target of around Rs 75. But Rs 50 and Rs 60 should be achievable in the next maybe one-three months time period."
Disclosure: I have recommended the above stock and I and my clients do have trading positions in the above stock.
